• Qiming Pang, Bangtao Li, Suli Zhang, Jiaoyang Li, and Shuo Gu.
• Department of Neuroscience, Hainan Women and Children's Medical Center, Hainan, China.
• Medicine (Baltimore). 2022 Feb 25; 101 (8): e28882e28882.

BackgroundTo systematically collect, critically evaluate, and synthesize current evidence with respect to the efficacy, safety, and tolerability of levetiracetam as mono- or adjunctive therapy for children and adolescents with all types of epilepsy.MethodsThe presentation of methods and results in this systematic review was performed according to the evaluation guidelines for health care interventions provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol. Literature retrieval will use the Cochrane Library, Web of Science, PubMed, Embase, Allied and Complementary Medicine Database, China Biomedical Literature Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Database, and Ongoing Clinical Trials Database.The risk of bias of included studies is estimated by taking into consideration the characteristics including random sequence generation, allocation concealment, blinding of patients, blinding of outcome assessment, completeness of outcome data, selective reporting and other bias by Cochrane Collaboration's tool. Data synthesis and analyses are performed using RevMan 5.4 software.ResultsThe results of this systematic review and meta-analysis will be published in a peer-reviewed journal.ConclusionLevetiracetam seems to be effective and safe for the treatment of pediatric epilepsy.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

18 keywords...

hide…